CoreAge Rx vs RxPros
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and RxPros head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 65 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make RxPros a bad call — it's best for readers who can compare the full subscription commitment and obtain the precise formulation and pharmacy before paying. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | RxPros |
|---|---|---|
| Brief Score | 94/100 (A) | 65/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | Confirm full selected-term quote $99.99/month advertisement is paid annually; another section shows $134.99 under introductory or quarterly conditions. Three-month minimum or selected longer term applies; obtain full first charge and renewal schedule before payment. Full price detailsCompounded semaglutide offered; complete selected-term quote unknown; $99.99/month advertisement is paid annually, while another section shows $134.99/month under introductory or quarterly conditions; minimum commitment and initial invoice require confirmation |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | Confirm full selected-term quote $144.97/month advertisement is paid annually; another section shows $224.99 under introductory or quarterly conditions. Minimum commitment survives installments; cancellation after prescribing/pharmacy submission is generally final before shipment. Full price detailsCompounded tirzepatide offered; complete selected-term quote unknown; $144.97/month advertisement is paid annually, while another section shows $224.99/month under introductory or quarterly conditions; minimum commitment and initial invoice require confirmation |
| Coverage | US only; restrictions by state, confirmed at intake | Uses U.S. pharmacies and clinical review; complete current medication-specific state eligibility list is not established |
| Brand-name access | Not confirmed | Brand comparison figures do not establish current branded fulfillment through RxPros. |
| Oral / sublingual | Injection only | Unconfirmed |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
RxPros: Lowest $99.99/$144.97 monthly equivalents are paid annually; other sections show $134.99/$224.99 with introductory/quarterly conditions. Full selected first charge and renewal term unconfirmed.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.